PDS Biotechnology Corporation (PDSB) reported that results from its VERSATILE-002 Phase 2 trial of PDS0101, an HPV16-targeted immunotherapy, in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck cancer were published in JAMA Oncology. In the immune checkpoint inhibitor-naïve modified intention-to-treat population with PD-L1 CPS ≥ 1, median overall survival was 39.3 months, compared with a published 17.9 months for standard-of-care pembrolizumab regimens. Objective response rate for CPS ≥ 1 was 36%, versus a published 19% for standard-of-care pembrolizumab. The combination was reported as well-tolerated, with 13.8% Grade ≥3 treatment-related adverse events compared with a published 17% for pembrolizumab alone. PDS Biotechnology stated it continues to prioritize its PDS0301 program in metastatic colorectal cancer while pursuing a partnership strategy for PDS0101 and noted a recently announced PIPE financing of up to $22.3 million that includes a one-year exclusive right for NantWorks to negotiate an exclusive license to PDS0101.
PDS Biotechnology Corporation (PDSB) reports that Nant Capital, LLC, controlled by Patrick Soon-Shiong, has become a significant shareholder through participation in a private investment in public equity (PIPE). Nant Capital beneficially owns 20,336,335 shares of common stock, representing 19.9% of outstanding shares, including shares underlying exercisable warrants subject to a 19.9% beneficial ownership cap.
In the Initial Closing of the PIPE, Nant Capital purchased 13,005,334 shares of common stock and 22,392,896 Pre-Funded Warrants and received 17,699,115 Common Warrants, with per-unit prices around $0.28 and warrant exercise prices of $0.00033 and $0.22. A Milestone Closing tied to submission of a registrational Phase 3 protocol for PDS0301 will require Nant Capital to purchase an additional $10,000,000 of securities, also subject to the 19.9% cap.
Patrick Soon-Shiong and James Banaag have been appointed to the PDS Biotechnology board. As long as Nant Capital holds at least 15% of outstanding common stock (including Pre-Funded Warrant shares for this purpose), it may designate two directors. An Option Agreement grants an affiliate of Soon-Shiong an exclusive one-year right to negotiate an exclusive license for the PDS0101 program, in exchange for a $25,000 payment. Registration rights require PDS Biotechnology to register PIPE investors’ shares for resale within specified deadlines.
PDS Biotechnology Corp (PDSB) disclosed an initial ownership report showing that Dr. Patrick Soon-Shiong, through Nant Capital, LLC, is a director and ten percent owner holding indirect positions in common stock and warrants following a private placement that closed on September 14, 2026.
Nant Capital holds 13,005,334 shares of Common Stock, Pre-Funded Warrants exercisable into 22,392,896 shares at $0.0003 per share with no expiration, and Common Warrants exercisable into 17,699,115 shares at $0.2200 per share. Both warrant types include ownership limitations generally capped at 19.9% of issued and outstanding common stock, adjustable to no more than 19.99% upon 61 days’ prior notice.
PDS Biotechnology Corp (PDSB) reported that Arnold James Banaag is a director of the company in an initial statement of beneficial ownership on Form 3. The filing lists no equity holdings or transactions for him at this time, so it functions primarily as a role-identification disclosure.
PDS Biotechnology Corp (PDSB) furnished an updated corporate presentation highlighting progress in its oncology pipeline, centered on its tumor-targeted IL‑12 immunocytokine PDS0301 and HPV16 cancer vaccine PDS0101. In an NCI-led Phase 2 trial in microsatellite stable/mismatch repair‑proficient metastatic colorectal cancer with liver metastases, chemotherapy plus PDS0301 achieved a 71.4% objective response rate at six months and an approximate 80% 24‑month survival rate, with more than 380 patients dosed with PDS0301 across Phase 1 and 2 studies. A registrational Phase 3 protocol in metastatic colorectal cancer is in design.
The presentation notes a September 2026 financing led by Nant Capital, after which Patrick Soon‑Shiong, M.D., joined the board, and indicates that proceeds are intended to advance PDS0301 into late‑stage development, with an additional tranche committed upon submission of a Phase 3 protocol to the FDA. For PDS0101 plus pembrolizumab in first‑line HPV16‑positive recurrent/metastatic head and neck cancer, the VERSATILE‑002 study reported 39.3‑month median overall survival versus a published benchmark of 12–18 months, a 35.8% objective response rate, a 77.4% disease control rate, and 21% of patients experiencing 90–100% tumor regression. Multiple additional PDS0301 trials and five planned data readouts between Q4 2026 and Q2 2028 are outlined.
PDS Biotechnology Corp (PDSB) reported that Principal Accounting Officer Janetta Trochimiuk holds multiple employee stock options and common shares. The options cover blocks of 70,000, 30,000, 30,000, 25,000, 31,117, 27,750, 5,000, and 10,000 shares of common stock at exercise prices ranging from $0.98 to $11.61, expiring between December 9, 2029 and January 12, 2036. Some options vest over four years with 25% on the first anniversary and the remainder in 36 equal monthly installments, while others are already fully vested and exercisable. She also directly holds 1,124 shares of PDS Biotechnology common stock.
PDS Biotechnology Corporation (PDSB) completed the initial closing of a Private Investment in Public Equity (PIPE), raising $11.3 million in gross proceeds through the sale of common shares, pre-funded warrants and common warrants. Units of one share plus a warrant to purchase one-half share were priced at $0.2825, and units with a pre-funded warrant were priced at $0.28217. The company intends to use the net proceeds to repay outstanding indebtedness and for working capital, including development of its PDS0301 and PDS0101 immunotherapy programs. The PIPE, led by Nant Capital, LLC, includes a contingent milestone closing that would bring total proceeds in the transaction to up to $22.3 million if triggered. PDS Biotechnology also fully redeemed a $6.0 million 10% Yorkville promissory note for approximately $4.6 million, eliminating this debt with no early termination penalty. In connection with the financing, Nant obtained board designation rights and Dr. Patrick Soon-Shiong and James Banaag were appointed to PDS Biotechnology’s board of directors.
PDS Biotechnology Corp (PDSB) entered into a private PIPE financing with accredited investors, structured as an Initial Closing and a contingent Milestone Closing, for up to $22.55 million in equity and warrant securities. At the Initial Closing, PDS Biotech expects to raise approximately $11.55 million through units of common stock or pre-funded warrants plus accompanying one-year common warrants priced at $0.2825 per share unit and $0.28217 per pre-funded unit. Nant Capital and AB Group have committed a further $10 million and $1 million, respectively, at $0.22 per share (or $0.21967 per pre-funded warrant) upon submission of a registrational Phase 3 protocol for PDS0301. The company discloses that the maximum number of common shares issuable from the private placement, including warrant exercises, is 111,327,435 shares.
Nant will have the right to designate two directors, including Dr. Patrick Soon-Shiong, while it holds at least 15% of the outstanding common stock, and the board size has been increased from six to eight seats to accommodate these designees. PDS Biotech committed to maintain Nasdaq listing, reserve sufficient shares for warrant exercises, register the resale of the new securities with liquidated-damages protections for investors, and apply proceeds to repay indebtedness and fund working capital and clinical development. The company also granted NantWorks a one-year exclusive right to negotiate a potential exclusive license for its PDS0101 program.
PDS Biotechnology Corp (PDSB) reports that on August 31, 2026 it entered into a First Amendment to Promissory Note with YA II PN, Ltd., amending a promissory note originally issued on June 15, 2026 with an original principal amount of $6,000,000.
The amendment document is filed as an exhibit, but the specific modified terms are not described in the body of the report.
PDS Biotechnology Corp (symbol PDSB) reports that its Board approved a significant reduction in force to align operating expenses with strategic priorities and focus on advancing its PDS0301 program. The plan, approved on August 6, 2026, is expected to impact approximately 36% of the workforce and be substantially completed during the third quarter of 2026.
The company expects to record a one-time charge of about $842,000 in the third quarter of 2026 for employee separation benefits, all anticipated to be cash expenditures. PDS Biotechnology also states that additional, currently uncontemplated costs may arise and that actual results may differ materially from its estimates. Separately, effective August 21, 2026, the company terminated Chief Operating Officer Stephan Toutain without cause. Under his employment agreement, he is eligible for severance equal to 12 months of base salary, paid in installments, plus up to 12 months of company-paid COBRA health-care contributions, subject to signing a separation agreement and release of claims.